SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
InterMune (nasdaq)ITMN
An SI Board Since March 2000
Posts SubjectMarks Bans Symbol
508 37 0 ITMN
Emcee:  Secret_Agent_Man Type:  Unmoderated


InterMune Pharmaceuticals, Inc. develops and
commercializes innovative products for the treatment of
serious pulmonary and infectious diseases and congenital
disorders. The Company currently markets ACTIMMUNE©
(Interferon gamma-1b) Injection in the U.S. for the treatment
of Chronic Granulomatous Disease (CGD) and osteopetrosis.

Our Business

InterMune Pharmaceuticals develops and
commercializes innovative products for the
treatment of serious pulmonary and infectious
diseases and congenital disorders. We have the
exclusive license rights in the United States to
ACTIMMUNE© (interferon gamma-1b injection)
for a range of indications, including chronic
granulomatous disease, osteopetrosis, idiopathic
pulmonary fibrosis, mycobacterial infections,
systemic fungal infections and cystic fibrosis.

We currently market ACTIMMUNE for chronic
granulomatous disease. We have active
development programs underway for the other
indications, several of which are in mid- or
advanced-stage human testing, known as clinical
trials. Idiopathic pulmonary fibrosis,
mycobacterial infections and systemic fungal
infections are serious and difficult to treat
diseases that we believe represent a combined
potential market opportunity for ACTIMMUNE
of approximately $3.5 billion annually in the
United States.

Interferon gamma-1b, the active ingredient in
ACTIMMUNE, is a human protein which plays a
key role in preventing the formation of excessive
scar, or fibrotic, tissue and is a potent stimulator
of the immune system. Interferon gamma is
biologically distinct from interferon alpha and
interferon beta, two related proteins that are
currently marketed for the treatment of diseases
such as hepatitis B infection and multiple
sclerosis. Interferon gamma has a superior safety
profile as compared to interferon alpha and
interferon beta because it results in fewer and less
severe adverse side effects.

ACTIMMUNE

Marketed Indication

Chronic Granulomatous Disease. The U.S.
Food and Drug Administration has approved
ACTIMMUNE for the treatment of chronic
granulomatous disease, and we currently market
and sell ACTIMMUNE in the United States for
this disease. Chronic granulomatous disease is a
life-threatening congenital disorder of the immune
system that causes patients to be vulnerable to
severe recurrent infections. This disease affects
children, and no other FDA-approved treatment
currently exists. ACTIMMUNE was approved by
the FDA based on its ability to reduce the
frequency and severity of infections in these
patients.

Indications in Development

Osteopetrosis. In August 1999, upon the
completion of a Phase III clinical trial, we
submitted a supplement to our biologics license
application, or BLA, to the FDA for this
indication. The FDA has designated
osteopetrosis as eligible for both an accelerated
review, known as fast track review, and orphan
drug status. Osteopetrosis is a life-threatening,
congenital disorder in which an overgrowth of
bony structures leads to blindness, deafness and
increased susceptibility to infection. This disorder
primarily affects children, and no effective
treatment is currently available.

Idiopathic Pulmonary Fibrosis. We believe the
most significant near-term use of ACTIMMUNE
is for the treatment of idiopathic pulmonary
fibrosis, a life-threatening lung condition that
afflicts approximately 50,000 persons in the
United States. Idiopathic pulmonary fibrosis is
characterized by progressive scarring of the
lungs, which leads to their deterioration and
destruction. The prognosis of patients with
idiopathic pulmonary fibrosis is poor and most
patients die from progressive loss of lung
function, which leads to suffocation. Therapeutic
options for idiopathic pulmonary fibrosis are
limited and only minimally effective.

The results of a Phase II clinical trial published in
October 1999 in The New England Journal of
Medicine showed statistically significant
evidence that interferon gamma-1b halts and
reverses the progression of idiopathic pulmonary
fibrosis. We are continuing the clinical
development of ACTIMMUNE for idiopathic
pulmonary fibrosis by initiating a Phase II/III
pivotal clinical trial during the first half of 2000.

Other indications. We are also developing
ACTIMMUNE to treat a variety of other diseases,
including infectious diseases and cystic fibrosis.
Preclinical studies and clinical trials have
demonstrated the therapeutic potential of
ACTIMMUNE against a broad range of infectious
diseases, notably mycobacterial and systemic
fungal infections. A study published in May 1997
in The Lancet showed that ACTIMMUNE was
effective in the treatment of multidrug-resistant
tuberculosis, a type of mycobacterial infection. As
a result of these studies, we are initiating a Phase
III pivotal clinical trial for ACTIMMUNE in the
treatment of multidrug-resistant tuberculosis and
have commenced a Phase II clinical trial in
cryptococcal meningitis, a type of systemic fungal
infection. We intend to initiate Phase II clinical
trials in cystic fibrosis and in atypical
mycobacterial infections in the second half of
2000.

We believe that the risks and time required to
obtain FDA approval for new indications of
ACTIMMUNE may be reduced because
ACTIMMUNE has proven to be safe for patients
since its approval in 1990 for the treatment of
chronic granulomatous disease.

Other Products In Development

We also have two preclinical development
programs that address infections caused by two
types of bacteria, pseudomonas aeruginosa and
staphylococcus aureus. We believe that these
indications present combined market
opportunities of approximately $2 billion annually
in the United States.

Strategy

We plan to pursue a growth strategy through:

growing product revenue;
expanding the number of FDA-approved
indications for ACTIMMUNE;
enhancing physician awareness and
education;
developing a sales and marketing
organization to serve pulmonologists and
infectious disease specialists; and
continuing to in-license preclinical and
development-stage programs.

Background

InterMune was formed in 1998 and began
operations as a wholly-owned subsidiary of
Connetics Corporation. In 1998, Connetics
acquired from Genentech Inc., and subsequently
sublicensed to us, rights to develop and
commercialize ACTIMMUNE for a broad range
of indications. We initially focused on marketing
ACTIMMUNE for chronic granulomatous disease
and developing it for serious infectious diseases
and congenital disorders.

In October 1999, a study published in the The
New England Journal of Medicine showed
significant evidence that interferon gamma-1b
halts and reverses the progression of idiopathic
pulmonary fibrosis. As a result, we expanded our
development and commercialization plans to
include idiopathic pulmonary fibrosis as well as
other life-threatening pulmonary diseases.

intermune.com

did not see a thread so, i started one...
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
508And out from the cracks in the woodwork they rush forth..... Block &Savant-8/26/2014
507 Roche/ITMN Deal Hoists First Trust Biotech ETF to Record High -- MarSavant-8/26/2014
506 Roche to buy InterMune for $8.3 billionBy Jonathan D. RockoffSavant-8/25/2014
505 InterMune Receives FDA Breakthough Therapy Designation For PirfenidoSavant-7/28/2014
504 InterMune beats by $0.04, beats on revs; raises FY14 revs in-line wiSavant-5/13/2014
503I still have a position in ITMN though its not as big as it once was. I think tghmm-11/6/2013
502One Q on ITMN is where will the share price stabilize? Will it be in the low $1Biotech Jim-11/6/2013
501secondary killing ppshdl-11/6/2013
500In the FWIW column, the Baker Bros. Hedge Fund picked up a significant stake in Biotech Jim-12/12/2012
499Very Interesting study of Pirfenidone. I recall a very early pilot study that tghmm-12/1/2012
498Ian Estepan ?@ianestepan $ITMN May IMS data for Germany released:16% mo/mo growtghmm-7/5/2012
497Interesting article on Pirfenidone. Granted its a meta-analysis but should helpghmm-6/3/2012
496The other day Ian Estepan ? @ianestepan tweeted that IMS data showed 2 - 2.3 mighmm-6/2/2012
495Bosentan in IPF results are posted at clinicaltrials.gov. I am impressed with tghmm-6/2/2012
494Title: InterMune to Divest Actimmune® (Interferon Gamma-1b) Date(s): 5/21tnsaf-5/22/2012
493I don't think it's all that surprising that if you immune-suppress old pBiomaven-5/21/2012
492I found the imbalance in acute exacerbation very interesting especially given noghmm-5/21/2012
491One "standard" treatment turns out to be harmful: BACKGROUNDA combinBiomaven-5/20/2012
490Speaking of Fibrogen here is a link to the changes in their Phase 2 study (just ghmm-5/16/2012
489This issue of potential side effects came to mind when I saw the view from PK-PDBiotech Jim-5/16/2012
488Jim, do you think that there will be side effects of the CTGF mAb on chondrogenBiomaven-5/16/2012
487Below is that PR from Fibrogen. I do not disagree with you on this Peter, but I Biotech Jim-5/16/2012
486No doubt a second approved drug for IPF would hurt ITMN stock. I've heard Dghmm-5/16/2012
485But the Fibrogen IPF PR does create some new and substantial long-term risk hereBiomaven-5/15/2012
484In the FWIW column: I like the recent action in the ITMN stock since the latestBiotech Jim-5/7/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):